{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:16:51Z","timestamp":1787728611145,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Medical Research Council Singapore Open Fund Large Collaborative Grant","award":["NMRC\/LCG23 May\/0032"],"award-info":[{"award-number":["NMRC\/LCG23 May\/0032"]}]},{"DOI":"10.13039\/100028802","name":"STaR","doi-asserted-by":"crossref","award":["24-Jan-0005"],"award-info":[{"award-number":["24-Jan-0005"]}],"id":[{"id":"10.13039\/100028802","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40123-026-01323-2","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:57:30Z","timestamp":1770137850000},"page":"1057-1068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Initial Experiences of Switching to Aflibercept 8\u00a0mg for Neovascular Age-Related Macular Degeneration and Polypoidal Chorodal Vasculopathy in an Asian Population"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kikushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Y. C.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"14","key":"1323_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et\u00a0al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"1323_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et\u00a0al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"3","key":"1323_CR3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR\u202f: a randomized controlled trial. Adv Ther. 2020;37(3):1173\u201387.","journal-title":"Adv Ther"},{"issue":"1","key":"1323_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et\u00a0al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384.","journal-title":"Ophthalmology"},{"issue":"10326","key":"1323_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"8","key":"1323_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et\u00a0al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"issue":"9","key":"1323_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et\u00a0al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141(9):834\u201342.","journal-title":"JAMA Ophthalmol"},{"issue":"10432","key":"1323_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et\u00a0al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"key":"1323_CR9","doi-asserted-by":"crossref","unstructured":"Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, et\u00a0al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: 96-week results from the randomized phase 3 PULSAR trial. Ophthalmology. 2025.","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"1323_CR10","doi-asserted-by":"publisher","first-page":"1346322","DOI":"10.3389\/fopht.2023.1346322","volume":"3","author":"FNI Ibrahim","year":"2023","unstructured":"Ibrahim FNI, Teo KYC, Tan TE, Chan HH, Chandrasekaran PR, Lee SY, et\u00a0al. Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. Front Ophthalmol (Lausanne). 2023;3:1346322.","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"1323_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2024.1509065","volume":"4","author":"N Gilead","year":"2024","unstructured":"Gilead N, Chong YJ, Ibrahim FNI, Sun C, Teo KYC, Cheung CMG. Unexpected retinal fluid compartment responses with anti-VEGF therapy in polypoidal choroidal vasculopathy: a case report of four patients. Front Ophthalmol. 2024;4:1509065.","journal-title":"Front Ophthalmol"},{"key":"1323_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2025.08.034","volume":"280","author":"C Zhang","year":"2025","unstructured":"Zhang C, Aboukasm G, Lai DA, Leung N, Zhu D, Albini TA, et\u00a0al. Clinical efficacy of switching to faricimab in treatment resistant neovascular age-related macular degeneration: systematic review and meta-analysis. Am J Ophthalmol. 2025;280:248\u201366.","journal-title":"Am J Ophthalmol"},{"issue":"17","key":"1323_CR13","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et\u00a0al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023;37(17):3574\u201381.","journal-title":"Eye (Lond)"},{"issue":"5","key":"1323_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, et\u00a0al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125(5):708\u201324.","journal-title":"Ophthalmology"},{"issue":"4","key":"1323_CR15","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.4.17","volume":"10","author":"I Mantel","year":"2021","unstructured":"Mantel I, Mosinska A, Bergin C, Polito MS, Guidotti J, Apostolopoulos S, et\u00a0al. Automated quantification of pathological fluids in neovascular age-related macular degeneration, and its repeatability using deep learning. Transl Vis Sci Technol. 2021;10(4):17.","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"1323_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/IAE.0000000000003965","volume":"44","author":"L Ferro Desideri","year":"2024","unstructured":"Ferro Desideri L, Anguita R, Berger LE, Feenstra HMA, Scandella D, Sznitman R, et\u00a0al. Baseline spectral domain optical coherence tomographic retinal layer features identified by artificial intelligence predict the course of central serous chorioretinopathy. Retina. 2024;44(2):316\u201323.","journal-title":"Retina"},{"issue":"10","key":"1323_CR17","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.10.21","volume":"13","author":"L Ferro Desideri","year":"2024","unstructured":"Ferro Desideri L, Danilovska T, Bernardi E, Artemiev D, Paschon K, Hayoz M, et\u00a0al. Artificial intelligence-enhanced OCT biomarkers analysis in macula-off rhegmatogenous retinal detachment patients. Transl Vis Sci Technol. 2024;13(10):21.","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"1323_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, et\u00a0al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786\u201393.","journal-title":"JAMA Ophthalmol"},{"key":"1323_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, et\u00a0al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol. 2019;204:80\u20139.","journal-title":"Am J Ophthalmol"},{"key":"1323_CR20","unstructured":"Lee WK, Wong TY, Chen SJ, Sun X, Cheung CMG, Silva R, et\u00a0al. Aflibercept 8 mg in polypoidal choroidal vasculopathy: post hoc\u00a0analysis of PULSAR phase 3 trial. JAMA Ophthalmol. in revision."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01323-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01323-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01323-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:09:50Z","timestamp":1773151790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01323-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01323-2","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chui Ming Gemmy Cheung is an editorial board member of\n                      Ophthalmology and Therapy\n                      . Chui Ming Gemmy Cheung was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Wataru Kikushima and Kelvin Y.C. Teo declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"According to the policy of the Institutional Review Board (IRB) of the Singapore National Eye Centre, IRB approval was not required for retrospective audit of a single surgeon\u2019s (G.C.) outcome. Our IRB considered the activities in this work an audit of clinical outcome, which does not meet the definition of research activity. As such, their approval was not deemed to be required for the conduct of the activity or the publication of the results. This study adhered to the tenets of the Declaration of Helsinki. Patients\u2019 informed consent was waived for the reason described above.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}